⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484496 | 1.00 | — | — | |
| SCHEMBL13896478 | 0.69 | — | — | |
| SCHEMBL7408679 | 0.65 | — | — | |
| SCHEMBL3071846 | 0.64 | — | — | |
| SCHEMBL19288029 | 0.64 | — | — | |
| SCHEMBL13278640 | 0.64 | — | — | |
| SCHEMBL13278651 | 0.64 | — | — | |
| SCHEMBL5421537 | 0.64 | — | — | |
| SCHEMBL7490644 | 0.60 | — | — | |
| SCHEMBL14464237 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461338-B | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| EP-4143186-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | Pfizer Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698004-A | Azalactam compounds as HPK1 inhibitors | 辉瑞公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115461338-A | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021224818-A1 | ISOINDOLONE COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3880676-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Pfizer Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113316576-A | 2, 3-dihydro-1H-pyrrolo [3,4-c ] pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer | 辉瑞公司 | 2021-08-27 | — | — | CN | disclosed |
| WO-2020100027-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-2375904-A1 | BIARYL CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-1636181-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000809-A1 | SUBSTITUTED 3-ALKYL AND 3-ALKENYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | disclosed |